Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89885 | 0.91 | THRB (0.39) | THRBTSHRCHRM2CHRM4CHRM5 | |
| Sulfuric Acid Dimethyl Ester SCHEMBL4810305 | 0.85 | THRB (0.43) | THRBTSHRCHRM2CHRM4CHRM5 | |
| Sulfuric Acid Dimethyl Ester SCHEMBL462142 | 0.83 | — | — | |
| Methanesulfonic Acid Methyl Ester SCHEMBL28802093 | 0.78 | THRB (0.44) | THRBTSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL127614 | 0.77 | THRB (0.43) | THRBTSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL4400065 | 0.77 | — | — | |
| Sulfuric Acid Dimethyl Ester SCHEMBL27866743 | 0.76 | OR51E2 (0.35) | THRBTSHRCHRM2CHRM4CHRM5 | |
| Ammonia Solution, Strong SCHEMBL28986897 | 0.76 | THRB (0.42) | THRBTSHRCHRM2CHRM4CHRM5 | |
| Water SCHEMBL28394473 | 0.76 | THRB (0.42) | THRBTSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL5442968 | 0.76 | THRB (0.42) | THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553927-B1 | GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | ELAN PHARMA INT LTD (IE) | 2010-11-10 | — | — | EP | claimed |
| US-6908626-B2 | Compositions having a combination of immediate release and controlled release characteristics | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-06-21 | — | — | US | claimed |
| US-20240122855-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ICEUTICA PTY LTD. (AU) | 2024-04-18 | — | — | US | disclosed |
| US-20220054418-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ICEUTICA PTY LTD. (AU) | 2022-02-24 | — | — | US | disclosed |
| US-20200360294-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD. (AU) | 2020-11-19 | — | — | US | disclosed |
| EP-2054042-B1 | METHODS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE COMPOUNDS IN NANOPARTICULATE FORM | ICEUTICA PTY LTD (AU) | 2020-04-29 | — | — | EP | disclosed |
| US-20180369145-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ICEUTICA PTY LTD. (AU) | 2018-12-27 | — | — | US | disclosed |
| US-20180169028-A1 | Nanoparticle Composition and Methods for Synthesis Thereof | ICEUTICA PTY LTD. (AU) | 2018-06-21 | — | — | US | disclosed |
| US-20170281786-A1 | COMPOSITIONS AND METHODS OF MAKING RAPIDLY DISSOLVING IONICALLY MASKED FORMULATIONS | NEOS THERAPEUTICS, LP | 2017-10-05 | — | — | US | disclosed |
| EP-1830824-B1 | NANOPARTICLE COMPOSITION AND METHODS FOR SYNTHESIS THEREOF | ICEUTICA PTY LTD (AU) | 2016-01-13 | — | — | EP | disclosed |
| US-20150004240-A1 | COMPOSITIONS AND METHODS OF MAKING RAPIDLY DISSOLVING IONICALLY MASKED FORMULATIONS | PFAB LP | 2015-01-01 | — | — | US | disclosed |
| US-20100055246-A1 | NUTRITION DELIVERY CAPSULES FOR FUNCTIONAL FOODS | KOREA UNIVERSITY HOLDINGS CO., LTD. (KR) | 2010-03-04 | — | — | US | disclosed |
| EP-2054042-A1 | METHODS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE COMPOUNDS IN NANOPARTICULATE FORM | Iceutica Pty Ltd. (AU) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008000042-A1 | METHODS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE COMPOUNDS IN NANOPARTICULATE FORM | ICEUTICA PTY LTD (AU) | 2008-01-03 | — | — | WO | disclosed |
| EP-1830824-A1 | NANOPARTICLE COMPOSITION AND METHODS FOR SYNTHESIS THEREOF | Iceutica Pty Ltd. (AU) | 2007-09-12 | — | — | EP | disclosed |
| US-20070092553-A1 | Compositions and methods of making rapidly dissolving lonically masked formulations | PFAB LP (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2006069419-A1 | NANOPARTICLE COMPOSITION AND METHODS FOR SYNTHESIS THEREOF | ICEUTICA PTY LTD (AU) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169028-A1 | Nanoparticle Composition and Methods for Synthesis Thereof | CD47, CTTN, RHOA | THRB 4821/4885TSHR 4595/4885CHRM2 4658/4885 |
| US-20200360294-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | CD47, CTTN, RHOA | THRB 4824/4885TSHR 4583/4885CHRM2 4652/4885 |
| US-20220054418-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ALPP, ALPG, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | THRB 3245/4885TSHR 4055/4885CHRM2 4539/4885 |
| US-20180369145-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ALPP, ALPG, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | THRB 3245/4885TSHR 4055/4885CHRM2 4539/4885 |
| US-20240122855-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ALPP, ALPG, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | THRB 3245/4885TSHR 4055/4885CHRM2 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.